Argus Research Remains a Buy on Zoetis (ZTS)

Argus Research analyst Jasper Hellweg maintained a Buy rating on Zoetis yesterday. The company’s shares closed yesterday at $118.26.

Easter Sale - 70% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Hellweg is a 4-star analyst with an average return of 7.7% and a 55.43% success rate. Hellweg covers the Healthcare sector, focusing on stocks such as Roche Holding, Biogen, and Novo Nordisk.

Zoetis has an analyst consensus of Moderate Buy, with a price target consensus of $145.80, which is a 23.29% upside from current levels. In a report released on March 31, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $128.00 price target.

Based on Zoetis’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $2.39 billion and a net profit of $603 million. In comparison, last year the company earned a revenue of $2.32 billion and had a net profit of $581 million

Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZTS in relation to earlier this year. Most recently, in February 2026, Kristin Peck, the CEO of ZTS sold 20,000.00 shares for a total of $2,540,864.00.